Immunology & Inflammation

AbbVie built one of the world's best-selling medicines in Humira, the anti-inflammatory biologic that reshaped the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease and held the position of the globe's top-revenue drug for over a decade. Spun out of Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie is listed on the New York Stock Exchange under the ticker ABBV and ranks among the largest pharmaceutical companies by market capitalisation. Immunology & Oncology Leadership Immunology remains the company's core franchise, anchored by Humira and its successors Skyrizi (risankizumab) and Rinvoq (upadacitinib), both of which have grown rapidly across multiple approved indications including plaque psoriasis, Crohn's disease and ulcerative colitis. In oncology , AbbVie markets Imbruvica (ibrutinib), a BTK inhibitor developed in partnership with Janssen, and Venclexta (venetoclax), a BCL-2 inhibitor co-developed with Roche, both indicated for certain blood cancers including chronic lymphocytic leukaemia. Neuroscience & Aesthetics Portfolio AbbVie significantly broadened its therapeutic reach with the 2020 acquisition of Allergan, one of the largest pharmaceutical mergers in history. That transaction brought the company Botox (both therapeutic and cosmetic), the migraine portfolio including Ubrelvy and Qulipta, and a range of medical aesthetics products. The neuroscience division now spans migraine prevention, movement disorders and psychiatry, with further pipeline candidates in Parkinson's disease and mood disorders. The aesthetics business, marketed under the Allergan Aesthetics brand, positions AbbVie as a leader in a segment beyond traditional pharmaceuticals. With operations spanning more than 70 countries and a global workforce numbering in the tens of thousands, AbbVie invests heavily in research and development, maintaining a broad pipeline across immunology, oncology, neuroscience and eye care. The company is a constituent of the S&P 500 and is widely followed for its progressive dividend policy. Further information is available at abbvie.com.

Accord Healthcare ranks among the fastest-growing generic and biosimilar medicines companies in Europe, distributing products across more than 80 countries and holding one of the largest market footprints of any European generic pharmaceutical business. Established as the European commercial arm of Intas Pharmaceuticals, an Indian pharmaceutical group headquartered in Ahmedabad, Accord operates its principal EMENA base from Uxbridge, United Kingdom, with additional commercial representation in Barcelona, Spain, and a growing network of affiliates across Eastern Europe. Therapeutic Portfolio and European Reach Accord's product portfolio is built around hospital and community settings across several key therapy areas. Its oncology and haematology range forms the largest segment of the business, complemented by lines covering autoimmune conditions and central nervous system disorders. The company has delivered successive year-on-year growth in the volume of medicines launched across European markets, with its most recent annual cycle yielding the largest portfolio rollout in the company's history. A dedicated European affiliate network, with national teams across Austria, Czech Republic, Finland, France, Germany, Ireland, Italy, the Netherlands, Poland, Romania, Slovakia, Spain and Sweden, provides the commercial infrastructure to support hospital tenders and retail pharmacy channels simultaneously. Biosimilars, Animal Health and Sustainability Beyond small-molecule generics, Accord Healthcare operates at the higher-complexity end of pharmaceutical development through its biosimilars programme, where regulatory pathways and development timelines mirror those of originator biologics. This positions the company among a relatively small group of European generics firms capable of competing in both chemical and biological medicine categories. Accord also maintains an animal health division, extending the group's reach across the broader life sciences sector, alongside a patient advocacy group function that signals engagement with patient outcomes beyond the purely commercial. The company publishes environment, social and governance reporting in line with expectations from institutional partners and regulated healthcare customers across the European Union and beyond. Further information is available at accord-healthcare.com.

Anchored in the science of human plasma, ADMA Biologics operates as a fully vertically integrated commercial biopharmaceutical company applying patented immunotechnology to develop, manufacture, and commercialise plasma-derived biologics for patients with serious immunological disorders. Listed on NASDAQ (ticker: ADMA) and headquartered in Boca Raton, Florida, the company controls each stage of its supply chain, from plasma collection through fill-finish manufacturing and medical affairs, a model that sets it apart from conventional pharmaceutical manufacturers dependent on external plasma suppliers. Commercial Portfolio and Plasma Collection ADMA's marketed products include ASCENIV, an intravenous immunoglobulin (IVIG) indicated for primary humoral immunodeficiency in adults and adolescents; BIVIGAM, a broad-spectrum IVIG therapy; and Nabi-HB, a hyperimmune globulin targeting hepatitis B. These products are manufactured at the company's FDA-licensed facility in Boca Raton. Plasma supply is secured through ADMA BioCenters, its own network of plasma collection centres operating across the United States, which feed proprietary immunotechnology fractionation processes downstream. Contract development and manufacturing services extend the company's commercial reach, allowing third-party biopharmaceutical partners to access ADMA's specialised biologics processing infrastructure. Scientific direction is guided by a dedicated Scientific Advisory Board, and the medical affairs function supports clinician engagement, publications, and advocacy for patients living with primary immunodeficiency disease. Further information is available at admabiologics.com.

Specialising in osteoarticular and inflammation-focused research, AGINKO operates as a contract research organisation (CRO) with a defined focus that distinguishes it from broader-scope service providers. The company concentrates on the musculoskeletal segment, deploying a team of experienced musculoskeletal experts to guide orthopaedic products and compounds through pre-clinical and clinical development pathways. Based in Marly, Switzerland, AGINKO Research AG serves clients across the pharmaceutical, biotechnology, and medical device industries. Its stated mission is to deliver high-quality pre-clinical laboratory services and clinical trial management with a commitment to both customer service and scientific rigour. The combination of pre-clinical and clinical capability within a single specialist organisation allows clients to progress compounds along the regulatory pathway without transferring to a separate provider at each stage. The company's service portfolio spans preclinical research, including disease models; clinical research services; histology and laboratory services; medical consultation and referral; and consulting covering due diligence. Histology services represent a particular operational capability, with preclinical histology slide processing cited among the company's operational activities. Regulatory and clinical process guidance for orthopaedic compounds is a core offering, reflecting the organisation's specialist positioning in the osteoarticular field. AGINKO serves clients globally across multiple countries, providing an international reach from its Swiss base. The company's focus on a defined therapeutic area, rather than a generalist CRO approach, positions it as a reference partner for organisations developing products in musculoskeletal and inflammatory conditions. Further information is available at aginko.com.

Dedicated entirely to Phase II-IV clinical trials , Albuquerque Clinical Trials has operated as a locally owned, independent research centre since 1988. Based in Albuquerque, New Mexico, the site conducts studies on behalf of pharmaceutical and biotechnology sponsors across a broad range of therapeutic areas. The facility's in-house team brings together board-certified physicians, a PharmD, certified study coordinators, licensed clinicians, regulatory specialists, recruitment professionals and data entry personnel. This integrated staffing model allows the centre to manage all phases of a trial from a single site, reducing sponsor coordination burden and supporting consistent data quality. The active study portfolio covers a diverse set of indications, including type I and type II diabetes , obesity-related conditions, weight loss, gout, heart failure prevention, systemic lupus erythematosus, coeliac disease, migraines, male incontinence, constipation and infectious disease, including a C. difficile vaccine programme. Birth control and menstrual migraine studies are also listed among current or recent therapeutic areas, reflecting the breadth of the clinical programme. The centre states its core commitments as exceeding sponsor expectations for dependability, human protection, subject enrolment and overall performance, with the broader aim of improving patient health through access to innovative therapies. Patient-facing infrastructure includes a dedicated sign-up pathway and a sponsor referral channel. Further information is available at abqct.com.

Allergy Therapeutics positions itself as a global pioneer of convenient treatment for allergy and immune-related disorders, operating as a publicly listed company (PLC) with commercial presence across Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom. A declared focus on patient convenience runs throughout the company's scientific and commercial model. The organisation frames convenience not as a secondary benefit but as a clinical imperative, recognising that treatment adherence in allergy immunotherapy depends on how manageable the regimen is for both healthcare professionals and patients. Its research and development programme reflects this, combining product development with a published body of investigator and consultant registry data. The company's adjuvant technology is commercialised through its Bencard Adjuvant Systems division, which sits alongside the core Allergy Therapeutics brand as a specialist unit serving healthcare partners and industry stakeholders. This dual structure signals a role that extends beyond direct-to-clinician supply into platform licensing and scientific collaboration. Investor-facing materials describe a defined business model, investment case, and strategy, consistent with a company that reports to public markets and maintains structured shareholder services. The breadth of its European footprint and the existence of a dedicated healthcare professional information channel indicate an established B2B and clinical relationships network. Further information is available at allergytherapeutics.com.

Founded in 1980 in Thousand Oaks, California, Amgen was one of the world's first biotechnology companies to industrialise the manufacture of proteins from living cells, a founding ambition that shaped modern biopharmaceuticals. Listed on Nasdaq under the ticker AMGN, Amgen has grown into one of the largest independent biotechnology companies globally, with operations spanning more than 100 countries and a workforce of tens of thousands. Core Therapy Areas and Pipeline Amgen's therapeutic focus covers oncology, haematology, cardiovascular disease, inflammation, bone health, and nephrology. The company's portfolio includes well-established products such as Enbrel for inflammatory conditions, Prolia and Xgeva for bone loss, and Repatha for cholesterol management. In oncology, its BiTE (bispecific T-cell engager) platform represents a distinctive approach to cancer immunotherapy , with Blincyto being one of the first approved BiTE molecules. The 2023 acquisition of Horizon Therapeutics expanded Amgen's rare disease capabilities, adding treatments for conditions such as thyroid eye disease and gout to its portfolio. Manufacturing and Global Infrastructure Amgen operates a substantial global manufacturing network, with large-scale biologics production facilities across the United States, Puerto Rico, Ireland, and Singapore. This internal manufacturing capability, built from the company's earliest years, gives Amgen end-to-end control over biologics production at commercial scale. The company has also invested in next-generation small molecule research alongside its biologics heritage, broadening its discovery toolkit. With decades of published research, long-standing academic and clinical partnerships, and a pipeline extending across multiple therapeutic categories, Amgen remains a central reference point for practitioners, researchers, and industry professionals working in the global pharmaceutical and biotechnology sector. Further information is available at amgen.com.

argenx built its reputation on a single, unusually productive starting point: the immune systems of llamas and other camelids, which produce a class of antibodies that proved to be a powerful foundation for engineering next-generation immunology medicines. From that scientific premise, the Belgian-American company has grown into one of the most closely watched names in immunology drug development , with a commercial product, VYVGART (efgartigimod alfa), approved in multiple markets for the treatment of generalised myasthenia gravis. Founded in 2008 and headquartered in Ghent, Belgium, with significant operations in the United States and Japan, argenx is listed on Nasdaq (ARGX) and on Euronext Brussels, reflecting its transatlantic scope. The company's pipeline is centred on FcRn biology, targeting the neonatal Fc receptor to reduce disease-causing IgG antibodies in a range of serious autoimmune conditions. This mechanism underpins efgartigimod in several additional indications under investigation, as well as other early-stage programmes in the portfolio. The company operates with a focused autoimmune disease strategy rather than pursuing broad therapeutic diversification, concentrating resources on conditions where dysregulated IgG antibodies drive pathology. Target areas include neuromuscular disease, haematology, and dermatology, among others under active clinical investigation. Further information is available at argenx.com.

ASLAN Pharmaceuticals is a dual-listed (NASDAQ: ASLN; Taiwan Stock Exchange) clinical-stage biopharmaceutical company headquartered in Singapore, with operations in Taiwan and the United States. Founded in 2010, the company concentrates its pipeline on inflammatory diseases and oncology, with a particular strategic emphasis on conditions where patients lack effective treatment options. The company's lead asset is farudodstat (ASLAN004), a monoclonal antibody that blocks both the IL-13 receptor alpha-1 and IL-4 receptor alpha subunits. This dual mechanism is designed to address the full spectrum of type 2 inflammation and is being evaluated in moderate-to-severe atopic dermatitis and ulcerative colitis. ASLAN Pharmaceuticals has conducted Phase 2 studies across these indications, with clinical data guiding its ongoing development strategy. Pipeline Focus and Business Model ASLAN Pharmaceuticals operates a capital-light model, progressing internally discovered compounds through clinical proof-of-concept before seeking regional or global partnership arrangements. The company has previously evaluated oncology assets including varlitinib, a pan-ErbB inhibitor studied in biliary tract cancer and gastric cancer, and retains scientific capabilities across both immunology and oncology drug discovery. With its Asia-Pacific base, ASLAN is positioned to run efficient clinical programmes in markets with high patient enrolment potential, supporting faster data generation across its therapeutic areas. Further information is available at aslanpharma.com.

AstraZeneca is one of the world's largest biopharmaceutical companies , with its global headquarters at the Cambridge Biomedical Campus in England. Founded in 1999 through the merger of Astra AB of Sweden and Zeneca Group of the United Kingdom, the company is listed on the London Stock Exchange (AZN) and on Nasdaq, and employs approximately 90,000 people across more than 100 countries. Cambridge functions not merely as a corporate address but as the centre of the company's worldwide research and early development capability, hosting thousands of scientists working across discovery biology, chemistry, and translational medicine. Therapy Areas and Pipeline The company's research strategy concentrates on three main therapy area clusters: oncology, cardiovascular, renal and metabolic disease (CVRM), and respiratory and immunology (R&I). Within oncology, AstraZeneca markets established medicines including osimertinib (Tagrisso), olaparib (Lynparza, developed with MSD), and durvalumab (Imfinzi). The CVRM portfolio includes dapagliflozin (Farxiga/Forxiga), which has received regulatory approvals across heart failure, chronic kidney disease, and type 2 diabetes indications. The respiratory franchise covers budesonide/formoterol combinations and the biologic tezepelumab (Tezspire, developed with Amgen) for severe asthma. UK Operations and Clinical Development AstraZeneca UK operates across the full pharmaceutical value chain: early and late-stage clinical trials , regulatory affairs, medical affairs, market access, and commercial operations serving the National Health Service. The UK site at Cambridge is complemented by manufacturing and biologics development capabilities at sites including Macclesfield. The company collaborates extensively with the Medical Research Council, Cancer Research UK, and NHS England, and was a prominent partner in the University of Oxford COVID-19 vaccine programme, through which AstraZeneca's Vaxzevria was manufactured and distributed globally at no profit during the pandemic period. AstraZeneca participates in hundreds of sponsored clinical studies in the United Kingdom at any given time, engaging NHS trusts, academic medical centres, and independent research sites. The organisation also operates a patient access programme infrastructure and maintains a dedicated UK medical information service for healthcare professionals. Further information is available at astrazeneca.co.uk.

Boehringer Ingelheim ranks among the largest research-driven pharmaceutical companies in the world and, uniquely for a business of its scale, remains wholly family-owned, having operated independently since its founding in Ingelheim am Rhein, Germany, in 1885. That private ownership shapes everything from its long investment horizon to its willingness to pursue complex biology that publicly listed peers may avoid. Human and Animal Health The company operates across two distinct businesses. Its human pharma division concentrates on respiratory diseases , cardiovascular and metabolic conditions, oncology, and immunology, with established medicines spanning COPD, heart failure, type 2 diabetes, and idiopathic pulmonary fibrosis. The animal health division is one of the largest in the world, covering livestock and companion animal health across a broad portfolio of vaccines and therapeutics, a segment reinforced by the 2017 asset swap with Sanofi that brought in Merial. Global Research & Biopharmaceutical Manufacturing Boehringer Ingelheim maintains a significant contract manufacturing presence alongside its own pipeline work. Its biopharmaceutical contract manufacturing organisation arm, among the longest-established in the industry, produces biologics for third-party clients as well as internal programmes. Research centres span Germany, Austria, the United States, China, and other locations, with the company consistently investing a substantial proportion of net sales back into research and development each year. Its pipeline spans small molecules, biologics, and cell and gene therapy technologies, reflecting a deliberate push into next-generation modalities. The group employs tens of thousands of people across more than 130 markets globally. Headquartered in Ingelheim am Rhein, the company's independent status means it publishes net sales rather than stock-market results, with figures consistently placing it within the global top-ten pharmaceutical groups by revenue. Its therapy focus on diseases with significant unmet need, combined with a long-term ownership model, gives it a research culture oriented toward decade-spanning programmes rather than quarterly targets. Further information is available at boehringer-ingelheim.com.

Bristol Myers Squibb has built its modern identity around a singular strategic conviction: that understanding the biology of serious disease at the molecular level is the fastest route to transformative medicines. The company traces its origins to 1887, and its current form emerged from the merger of Bristol-Myers and Squibb in 1989, creating one of the world's largest research-driven biopharmaceutical companies. It is listed on the New York Stock Exchange under the ticker BMY. Oncology & Immuno-Oncology Leadership The area where BMS has most visibly reshaped clinical practice is oncology , and specifically immuno-oncology. Opdivo (nivolumab) and Yervoy (ipilimumab) are among the most widely recognised checkpoint inhibitors in global oncology, having been approved across a broad range of tumour types. The company's acquisition of Celgene in 2019, one of the largest transactions in pharmaceutical history at the time, added Revlimid and a substantial haematology portfolio, reinforcing BMS's position in multiple myeloma and other blood cancers. Cardiovascular & Immunology Pipeline Beyond oncology, BMS has longstanding expertise in cardiovascular disease , with Eliquis (apixaban), developed in partnership with Pfizer, becoming one of the most prescribed oral anticoagulants worldwide. The immunology and fibrosis franchises have grown in strategic importance, with the company investing in targeted protein degradation and cell therapy as emerging modalities. CAR T platforms, brought in through the Celgene acquisition, represent a key area of next-generation oncology development. Headquartered in Princeton, New Jersey, BMS operates across more than 40 countries, with major research campuses in the United States and Europe. The company employs tens of thousands of people globally and maintains a significant presence in clinical development, running one of the pharmaceutical industry's larger late-stage trial portfolios at any given time. Its commercial and scientific scale, combined with a focused therapeutic strategy centred on serious diseases with high unmet need, places BMS among a small number of companies that consistently shape oncology, haematology and cardiovascular treatment standards worldwide. Further information is available at bms.com.